Medifast (MED) Earns Coverage Optimism Score of 0.20

News coverage about Medifast (NYSE:MED) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medifast earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the specialty retailer an impact score of 46.0464383457422 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research firms have recently commented on MED. Zacks Investment Research lowered shares of Medifast from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. DA Davidson upped their target price on shares of Medifast to $89.00 and gave the stock a “buy” rating in a research report on Friday, December 8th. ValuEngine lowered shares of Medifast from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Sidoti reiterated a “neutral” rating and issued a $55.00 target price (up from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $74.33.

Shares of Medifast (NYSE:MED) opened at $72.16 on Friday. The stock has a market cap of $851.70, a PE ratio of 35.37, a price-to-earnings-growth ratio of 1.80 and a beta of 0.50. Medifast has a 1 year low of $40.00 and a 1 year high of $74.78.

Medifast (NYSE:MED) last issued its quarterly earnings data on Tuesday, November 7th. The specialty retailer reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. The firm had revenue of $77.20 million during the quarter, compared to the consensus estimate of $74.94 million. Medifast had a net margin of 8.58% and a return on equity of 24.07%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.51 earnings per share. analysts forecast that Medifast will post 2.17 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 8th. Investors of record on Friday, December 22nd will be paid a $0.48 dividend. This is an increase from Medifast’s previous quarterly dividend of $0.32. This represents a $1.92 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date is Thursday, December 21st. Medifast’s dividend payout ratio is presently 94.12%.

In related news, Director Glenn W. Welling sold 275,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $64.60, for a total value of $17,765,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glenn W. Welling sold 250,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $65.00, for a total transaction of $16,250,000.00. The disclosure for this sale can be found here. 5.40% of the stock is owned by corporate insiders.

WARNING: “Medifast (MED) Earns Coverage Optimism Score of 0.20” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at

About Medifast

Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.

Insider Buying and Selling by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with's FREE daily email newsletter.

Leave a Reply